Gonadorelin vs HCG on TRT: What Changed and Why It Matters

If you've been following the TRT world for the past few years, you've noticed a shift. HCG — the gold standard adjunct to testosterone therapy for decades — became harder to get and more expensive. In its place, a drug called gonadorelin started showing up on protocol sheets. Clinics that used to prescribe HCG routinely switched to gonadorelin almost overnight.

But are they interchangeable? Not exactly. And understanding why matters if you're on TRT and trying to preserve fertility, testicular function, or both.

What Happened to HCG?

In March 2020, the Biologics Control Act reclassified HCG as a biologic product rather than a drug. This moved it from FDA drug regulation to FDA biologic regulation, which affected compounding pharmacies significantly.

Previously, compounding pharmacies could produce HCG under the Federal Food, Drug, and Cosmetic Act. Under biologic classification, the regulatory requirements changed. Many compounding pharmacies stopped producing HCG because the new compliance requirements were too burdensome or costly.

Brand-name HCG products (Pregnyl, Novarel) remained available, but they're significantly more expensive — often $200-400+ per month compared to $30-60 for compounded HCG.

The result: millions of men on TRT who relied on affordable compounded HCG suddenly needed an alternative. Enter gonadorelin.

What Is Gonadorelin?

Gonadorelin is a synthetic version of GnRH (gonadotropin-releasing hormone) — the hormone your hypothalamus naturally produces to tell your pituitary gland to release LH and FSH.

In a normally functioning system, GnRH is released in pulses. Each pulse triggers a burst of LH and FSH from the pituitary, which then signals the testes to produce testosterone and sperm.

Gonadorelin mimics this natural signaling. When administered in a pulsatile fashion (intermittent subcutaneous injections), it stimulates the pituitary to release LH and FSH, which then stimulate the testes.

How Gonadorelin Differs from HCG

This is where the nuance matters.

HCG acts directly on the testes. It mimics LH at the testicular level, bypassing the brain entirely. It binds to the same receptors as LH on Leydig cells, directly stimulating testosterone production and maintaining intratesticular testosterone levels. The pituitary is not involved.

Gonadorelin acts on the pituitary. It tells the pituitary to produce LH and FSH, which then act on the testes. It works one step upstream from where HCG works.

Here's the problem: when you're on TRT, your hypothalamus and pituitary are suppressed by the exogenous testosterone. Your brain has already shut down GnRH production because it detects adequate (or supraphysiologic) testosterone levels. The pituitary, chronically unstimulated, may become less responsive over time.

So when you inject gonadorelin to stimulate an already-suppressed pituitary, the response may be blunted. The pituitary might not produce much LH or FSH in response, especially if the patient has been on TRT for months or years.

With HCG, this isn't an issue. HCG doesn't care what the pituitary is doing. It goes directly to the testes and says "work."

The Evidence Gap

Here's the uncomfortable truth: there's limited clinical evidence that gonadorelin is as effective as HCG for the specific uses men on TRT care about — namely, preserving fertility and preventing testicular atrophy.

HCG has decades of research in men, including studies specifically examining:

• Spermatogenesis maintenance on TRT
• Testicular volume preservation
• Intratesticular testosterone levels
• Fertility outcomes

Gonadorelin's data in the context of concurrent TRT is much thinner. The theoretical mechanism is sound, but the clinical proof is not as established. Much of what we know about gonadorelin's effectiveness in this context comes from clinical experience rather than randomized controlled trials.

This doesn't mean gonadorelin doesn't work. It means we're less certain about how well it works compared to HCG in this specific application.

Practical Differences

Dosing and Administration

HCG: Typically 500-1500 IU subcutaneously, two to three times per week. The half-life is relatively long (about 24-36 hours), allowing for every-other-day or three-times-weekly dosing.

Gonadorelin: Typically 100-400 mcg subcutaneously, twice daily or every other day. Because gonadorelin has a very short half-life (minutes), it needs to be administered more frequently to simulate pulsatile GnRH release.

The dosing frequency is a practical disadvantage. Going from three injections per week (HCG) to twice-daily injections (gonadorelin) is a significant increase in injection burden. Some protocols use less frequent dosing, but this may reduce effectiveness since pulsatile administration is thought to be important.

Cost

Compounded gonadorelin is generally affordable — comparable to what compounded HCG used to cost. Brand-name HCG is significantly more expensive. If cost is the primary driver, gonadorelin has the advantage.

Stability and Storage

Both require reconstitution and refrigeration. Gonadorelin's shorter stability after reconstitution can be a practical concern.

Monitoring

On HCG, monitoring is straightforward — check testosterone, estradiol, and semen analysis if fertility is a concern.

On gonadorelin, you can also check LH levels to see if the pituitary is responding. If LH doesn't rise with gonadorelin use, the drug likely isn't working effectively in that patient.

When Each Option Makes Sense

Choose HCG when:

• Fertility preservation is a critical priority
• Testicular atrophy prevention is important to you
• You can access and afford brand-name HCG
• You've been on TRT long-term and pituitary suppression is significant
• You want the most evidence-backed option

Choose gonadorelin when:

• HCG is not available or affordable
• You want a more physiologic approach (stimulating the natural cascade)
• You're newer to TRT and your pituitary is still relatively responsive
• Your provider monitors LH levels to confirm response
• You're comfortable with more frequent dosing

Consider other alternatives:

• Enclomiphene — stimulates the brain's GnRH production, which then drives LH and FSH. Can be used alongside TRT or as an alternative. (See our [enclomiphene vs TRT comparison](/articles/enclomiphene-vs-trt).)
• FSH injections — for men specifically concerned about sperm production, recombinant FSH can be added to a protocol, though cost is high.

What This Means for Your Protocol

If you're currently on TRT with gonadorelin and things are working — you feel good, testicular volume is maintained, and fertility (if relevant) isn't a concern — there may be no reason to change.

If you're on gonadorelin and experiencing testicular atrophy, declining testicular volume on exam, or fertility problems, it may be worth pursuing brand-name HCG despite the cost. The direct mechanism of action provides more reliable testicular stimulation in the setting of pituitary suppression.

The critical step is monitoring. Don't assume gonadorelin is working — verify it with lab work (LH, semen analysis if applicable) and clinical assessment (testicular volume).

The Bottom Line

Gonadorelin is a reasonable alternative to HCG, but calling it a perfect replacement oversells the evidence. The regulatory change that pushed clinics toward gonadorelin was driven by availability and economics, not by superior clinical data.

As a patient, you deserve to know this. You deserve to understand why your protocol was changed, what the trade-offs are, and what monitoring should look like. This isn't about one drug being good and the other being bad — it's about informed decision-making.

At CORAL, we discuss these nuances with every TRT patient. Whether you're on HCG, gonadorelin, or considering your options, we make protocol decisions based on your goals, your labs, and the best available evidence.

Have questions about your TRT protocol? [Schedule a consultation](https://coral.clinic/start) with CORAL — we help men across Florida optimize their hormone therapy.